Tags

Type your tag names separated by a space and hit enter

17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
J Infect. 2016 06; 72(6):713-722.JI

Abstract

BACKGROUND

The 17D live attenuated yellow fever (YF) vaccine is contra-indicated in immune-compromised individuals and may elicit a suboptimal immunologic response. The aim of this study is to assess whether long-term immune responses against the YF vaccine are impaired in immune-compromised patients.

MATERIALS AND METHODS

Fifteen patients using different immunosuppressive drugs and 30 healthy individuals vaccinated 0-22 years ago were included. The serological response was measured using the plaque reduction neutralization test (PRNT). CD8(+) and CD4(+) T-cell responses were measured following proliferation and re-stimulation with YFV peptide pools. Phenotypic characteristics and cytokine responses of CD8(+) T-cells were determined using class I tetramers.

RESULTS

The geometric mean titre of neutralizing antibodies was not different between the groups (p = 0.77). The presence of YFV-specific CD4(+) and CD8(+) T-cell did not differ between patients and healthy individuals (15/15, 100.0% vs. 29/30, 96.7%, p = 0.475). Time since vaccination correlated negatively with the number of YFV-specific CD8(+) T-cells (r = -0.66, p = 0.0045). Percentages of early-differentiated memory cells increased (r = 0.67, p = 0.017) over time.

CONCLUSION

These results imply that YF vaccination is effective despite certain immunosuppressive drug regimens. An early-differentiated memory-like phenotype persisted, which is associated with effective expansion upon re-encounter with antigen, suggesting a potent memory T-cell pool remains.

Authors+Show Affiliations

Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: rosannewieten@icloud.com.Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.Institute for Tropical Diseases, Harbour Hospital, Rotterdam, the Netherlands.Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.Renal Transplant Unit, Division of Internal Medicine, Academic Medical Center, the Netherlands.Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27017899

Citation

Wieten, R W., et al. "17D Yellow Fever Vaccine Elicits Comparable Long-term Immune Responses in Healthy Individuals and Immune-compromised Patients." The Journal of Infection, vol. 72, no. 6, 2016, pp. 713-722.
Wieten RW, Goorhuis A, Jonker EFF, et al. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. J Infect. 2016;72(6):713-722.
Wieten, R. W., Goorhuis, A., Jonker, E. F. F., de Bree, G. J., de Visser, A. W., van Genderen, P. J. J., Remmerswaal, E. B. M., Ten Berge, I. J. M., Visser, L. G., Grobusch, M. P., & van Leeuwen, E. M. M. (2016). 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. The Journal of Infection, 72(6), 713-722. https://doi.org/10.1016/j.jinf.2016.02.017
Wieten RW, et al. 17D Yellow Fever Vaccine Elicits Comparable Long-term Immune Responses in Healthy Individuals and Immune-compromised Patients. J Infect. 2016;72(6):713-722. PubMed PMID: 27017899.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. AU - Wieten,R W, AU - Goorhuis,A, AU - Jonker,E F F, AU - de Bree,G J, AU - de Visser,A W, AU - van Genderen,P J J, AU - Remmerswaal,E B M, AU - Ten Berge,I J M, AU - Visser,L G, AU - Grobusch,M P, AU - van Leeuwen,E M M, Y1 - 2016/03/24/ PY - 2016/01/16/received PY - 2016/02/26/revised PY - 2016/02/28/accepted PY - 2016/3/29/entrez PY - 2016/3/29/pubmed PY - 2017/10/7/medline KW - 17D yellow fever KW - Immune-compromised KW - Vaccination SP - 713 EP - 722 JF - The Journal of infection JO - J. Infect. VL - 72 IS - 6 N2 - BACKGROUND: The 17D live attenuated yellow fever (YF) vaccine is contra-indicated in immune-compromised individuals and may elicit a suboptimal immunologic response. The aim of this study is to assess whether long-term immune responses against the YF vaccine are impaired in immune-compromised patients. MATERIALS AND METHODS: Fifteen patients using different immunosuppressive drugs and 30 healthy individuals vaccinated 0-22 years ago were included. The serological response was measured using the plaque reduction neutralization test (PRNT). CD8(+) and CD4(+) T-cell responses were measured following proliferation and re-stimulation with YFV peptide pools. Phenotypic characteristics and cytokine responses of CD8(+) T-cells were determined using class I tetramers. RESULTS: The geometric mean titre of neutralizing antibodies was not different between the groups (p = 0.77). The presence of YFV-specific CD4(+) and CD8(+) T-cell did not differ between patients and healthy individuals (15/15, 100.0% vs. 29/30, 96.7%, p = 0.475). Time since vaccination correlated negatively with the number of YFV-specific CD8(+) T-cells (r = -0.66, p = 0.0045). Percentages of early-differentiated memory cells increased (r = 0.67, p = 0.017) over time. CONCLUSION: These results imply that YF vaccination is effective despite certain immunosuppressive drug regimens. An early-differentiated memory-like phenotype persisted, which is associated with effective expansion upon re-encounter with antigen, suggesting a potent memory T-cell pool remains. SN - 1532-2742 UR - https://www.unboundmedicine.com/medline/citation/27017899/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-4453(16)00082-7 DB - PRIME DP - Unbound Medicine ER -